Please assess the completion status of the following clinical trial:

Trial Title: Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
* Patients must have received either 2 or 3 prior chemotherapy regimens including adjuvant or neoadjuvant therapy.~* Prior treatment must have included both an anthracycline (i.e., doxorubicin or epirubicin) and a taxane (i.e., paclitaxel or docetaxel).~* Patients must have received a minimum cumulative dose of anthracycline or must be resistant to an anthracycline.~* Patients must be resistant to taxane therapy.~* Patients may not have any history of brain and/or leptomeningeal metastases.~* Patients may not have CTC Grade 2 or greater neuropathy (motor or sensory).~* Patients may have not have had prior treatment with an epothilone and/or capecitabine (i.e., Xeloda)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None
- B (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).